Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease
NCT06401044Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of AMG 732 in thyroid eye disease (TED), sponsored by Amgen. Started May 2024; status: active, not recruiting.
02
Drugs
AMG 732
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06401044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401044.